Pembrolizumab-induced Stevens-Johnson Syndrome with Severe Ocular Complications

Purpose: To report a unique case of Stevens-Johnson syndrome (SJS) with severe ocular complications induced by pembrolizumab, an immune checkpoint inhibitor. Case presentation: A 64-year-old man with urothelial cancer presented with bilateral corneal epithelial defect and conjunctival pseudo-membrane formation with erythematous patches on the four extremities, abdomen, and back. He had urothelial cancer with multifocal lesions in the renal pelvis and left ureter, and para-aortic metastatic lymph nodes. Accordingly, pembrolizumab treatment was planned. Generalized skin eruption occurred 4 days after the first cycle of pembrolizumab treatment, and ocular symptoms occurred 2 weeks after the first cycle. The patient's symptoms improved after cessation of pembrolizumab treatment and administration of steroids systemically. Conclusions: Immune checkpoint inhibitors, including pembrolizumab, have been developed recently and are widely used in the treatment of various cancers. However, it should be noted that the drugs may cause adverse events such as SJS with severe ocular complications.

Automated summary

This case report highlights a unique case of Stevens-Johnson syndrome with severe ocular complications induced by pembrolizumab, an immune checkpoint inhibitor. The patient's symptoms improved after cessation of pembrolizumab treatment and administration of steroids systemically. Immune checkpoint inhibitors have been widely used in cancer treatment, but may lead to adverse events, such as SJS with severe ocular complications.